Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.
BACKGROUND: Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in evaluating these therapies in earlier stages of disease. The recommended primary outcome for combination trials was progression-free survival and overall survival, with an alpha-recycling strategy.
BACKGROUND: Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in evaluating these therapies in earlier stages of disease. The recommended primary outcome for combination trials was progression-free survival and overall survival, with an alpha-recycling strategy.
What the study was
- Study design
- Observational Study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Gut
Why it surfaced
Topic: Novel therapeutics immunotherapy CAR-T; Score 6/10 → STANDARD priority
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.